COVID-19 News: The fourth dose of vaccine can’t prevent Omicron infections

Health Health Trending

According to a preliminary study in Israel, the fourth dose of COVID-19 vaccination raises antibodies to even greater levels than the third dose, but it is insufficient to prevent Omicron infections.

According to Gili Regev-Yochay, director of the Infectious Diseases Unit at Israel’s Sheba Medical Center, the Pfizer booster was given to 154 people after two weeks and the Moderna booster was given to 120 people after one week in a trial among its personnel.

Within two years, Moderna hopes to produce a single booster vaccine that protects against both Covid-19 and flu, according to its CEO, who also stated that data for an Omicron-specific vaccine will most likely be available in March.

While the coronavirus will continue to spread for many years, Pfizer’s chief executive, Albert Bourla, has stated that this current wave should be the last to necessitate restrictions.

In comparison to the fourth quarter of 2019, the International Labor Organization reduced its employment projection, anticipating a global shortfall of 52 million full-time jobs in 2022. According to the ILO, worldwide unemployment will continue above pre-pandemic levels until at least 2023. The Geneva-based group warned Monday that the uncertainty produced by Covid-19 variations is still weighing on the employment market, particularly in low- and lower-middle-income nations.

According to Regev-Yochay, the vaccines increased the number of antibodies “even a little bit more than what we had after the third dose.”

“Yet,” she told reporters, “this is probably not enough for the Omicron.” “We know by now that the level of antibodies required to defend against Omicron infection, even if the vaccine is effective, is probably too high for the vaccination.”

The findings were preliminary and not yet published, according to the hospital, and were the first of their sort in the globe.

Last month, Israel began offering a fourth injection, or a second booster, to the most vulnerable and high-risk groups, after becoming the fastest country to carry out initial COVID-19 immunizations a year ago.